NCT05677919View on ClinicalTrials.gov

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

November 11, 2026

Study Completion Date

September 3, 2030

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood, tissue, stool, and saliva samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI scan

DRUG

Pirtobrutinib

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Venetoclax

Given PO

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Biopsy

Undergo tissue biopsy

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER